Drug Monograph Updates | Pharmaceutical, OTC & Generic Drug Info https://www.empr.com/home/news/drug-monograph-updates/ Mon, 15 Apr 2024 19:01:50 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.empr.com/wp-content/uploads/sites/7/2023/03/cropped-empr-32x32.jpg Drug Monograph Updates | Pharmaceutical, OTC & Generic Drug Info https://www.empr.com/home/news/drug-monograph-updates/ 32 32 March 2024 Recap of Drug Updates https://www.empr.com/home/news/march-2024-recap-of-drug-updates/ Thu, 11 Apr 2024 20:35:34 +0000 https://www.empr.com/?p=218636 The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of March. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
ALTOPREV (Lovastatin) X X X X X      
BESPONSA (Inotuzumab ozogamicin) X X   X        
BREYANZI (Lisocabtagene maraleucel) X X       X    
DOVATO (Dolutegravir) X X   X X   X  
FANAPT (Iloperidone) X X   X   X    
FURADANTIN (Nitrofurantoin)   X X X     X  
LIVMARLI (Maralixibat) X X X X   X    
VAGIFEM (Estradiol [as hemihydrate])     X X X X    
VYTORIN (Ezetimibe, simvastatin) X X X X X      
ZOKINVY (Lonafarnib)   X X X X      
Review more drug monograph updates

]]> February 2024 Recap of Drug Updates https://www.empr.com/home/news/february-2024-recap-of-drug-updates/ Fri, 01 Mar 2024 21:12:07 +0000 https://www.empr.com/?p=216492 The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of February. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
BALVERSA (Erdafitinib) X X   X X X    
BELBUCA (Buprenorphine) X     X   X    
BILTRICIDE (Praziquantel)     X   X X    
BOSULIF (Bosutinib) X X       X X  
CETROTIDE (Cetrorelix [as acetate])     X  X   X    
DUPIXENT (Dupilumab) X X         X  
GAMMAGARD LIQUID (Immune globulin [human]) X X   X   X   X
HYQVIA (Immune globulin [human], recombinant human hyaluronidase) X X X     X    
MS CONTIN (Morphine sulfate) X     X   X    
XALKORI (Crizotinib)    X   X     X  
Review more drug monograph updates

]]> January 2024 Recap of Drug Updates https://www.empr.com/home/news/january-2024-recap-of-drug-updates/ Fri, 09 Feb 2024 14:17:14 +0000 https://www.empr.com/?p=215282 The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of January. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
BALVERSA (Erdafitinib) X X   X X X    
BELBUCA (Buprenorphine) X     X   X    
BILTRICIDE (Praziquantel)     X   X X    
BOSULIF (Bosutinib) X X       X X  
CETROTIDE (Cetrorelix [as acetate])     X  X   X    
DUPIXENT (Dupilumab) X X         X  
GAMMAGARD LIQUID (Immune globulin [human]) X X   X   X   X
HYQVIA (Immune globulin [human], recombinant human hyaluronidase) X X X     X    
MS CONTIN (Morphine sulfate) X     X   X    
XALKORI (Crizotinib)    X   X     X  
Review more drug monograph updates

]]> December 2023 Recap of Drug Updates https://www.empr.com/home/news/december-2023-recap-of-drug-updates/ Thu, 04 Jan 2024 15:44:41 +0000 https://www.empr.com/?p=213443 The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
COTEMPLA XR-ODT (Methylphenidate)       X X X    
CRESEMBA (Isavuconazonium sulfate)   X   X X   X   
DESOXYN (Methamphetamine HCl)     X X   X    
DEXEDRINE SPANSULE (Dextroamphetamine sulfate)     X X        
DYANAVEL XR ORAL SUSPENSION (Amphetamine)   X   X     X  
ORENCIA (Abatacept) X X            
SARCLISA (Isatuximab-irfc)       X X      
TARPEYO (Budesonide) X X   X        
TIROSINT-SOL (Levothyroxine sodium)   X   X X      
WELIREG (Belzutifan) X     X   X    
Review more drug monograph updates

]]> November 2023 Recap of Drug Updates https://www.empr.com/home/news/november-2023-recap-of-drug-updates/ Fri, 01 Dec 2023 16:13:37 +0000 https://www.empr.com/?p=211231 The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of November. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
ADZENYS XR-ODT (Amphetamine)     X X        
AZSTARYS (Serdexmethylphenidate, dexmethylphenidate)       X X X    
BREO ELLIPTA (Fluticasone furoate, vilanterol) X X            
CONCERTA (Methylphenidate)     X X X X    
COPAXONE (Glatiramer acetate)   X   X        
DAYTRANA (Methylphenidate)     X X X X     
ENBREL (Etanercept) X X         X  
IDACIO (Adalimumab-aacf) X X         X   
KINEVAC (Sincalide)     X X X      
MULTAQ (Dronedarone)     X X   X X  
Review more drug monograph updates

]]> October 2023 Recap of Drug Updates https://www.empr.com/home/news/october-2023-recap-of-drug-updates/ Fri, 03 Nov 2023 20:12:31 +0000 https://www.empr.com/?p=209609 The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
ABRILADA (Adalimumab-afzb) X X         X  
BRAFTOVI (Encorafenib) X X   X   X    
ENTYVIO (Vedolizumab) X X         X   
MEKTOVI (Binimetinib) X X   X   X    
OXBRYTA (Voxelotor)   X   X   X X  
STEGLATRO (Ertugliflozin) X   X X     X  
TEMODAR INJECTION (Temozolomide) X X   X   X X  
TIBSOVO (Ivosidenib) X X   X   X    
VABYSMO (Faricimab-svoa) X X   X        
ZORTRESS (Everolimus)  X     X X X    
Review more drug monograph updates

]]> September 2023 Recap of Drug Updates https://www.empr.com/home/news/september-2023-recap-of-drug-updates/ Tue, 03 Oct 2023 20:19:29 +0000 https://www.empr.com/?p=207876 The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of September. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
COMIRNATY (COVID-19 vaccine) X X   X     X  
COSENTYX (Secukinumab)   X   X     X   
CYLTEZO (Adalimumab-adbm) X X         X   
EZALLOR SPRINKLE (Rosuvastatin [as calcium]) X X X X X      
JARDIANCE (Empagliflozin) X X X  X        
OMECLAMOX-PAK (Omeprazole, clarithromycin, amoxicillin)     X   X     X
SPIKEVAX (COVID-19 vaccine) X X   X     X  
TRINTELLIX (Vortioxetine)       X X   X   
ZEPOSIA (Ozanimod)   X   X   X    
ZOLOFT (Sertraline)       X X   X  
Review more drug monograph updates

]]> August 2023 Recap of Drug Updates https://www.empr.com/home/news/august-2023-recap-of-drug-updates/ Tue, 05 Sep 2023 17:08:33 +0000 https://www.empr.com/?p=206201 The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of August. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
AMJEVITA (Adalimumab-atto) X X         X  
ILARIS (Canakinumab) X X       X    
INGREZZA (Valbenazine) X X   X   X X   
INVOKANA (Canagliflozin) X X X X        
INVOKAMET (Canagliflozin, metformin [as HCl] ext-rel) X X X  X        
LEQEMBI (Lecanemab-irmb)       X X X     
LONSURF (Trifluridine, tipiracil) X X   X        
NESINA (Alogliptin)       X   X    
ZEPZELCA (Lurbinectedin)   X     X      
ZETIA (Ezetimibe) X X X  X X X    
Review more drug monograph updates

]]> July 2023 Recap of Drug Updates https://www.empr.com/home/news/july-2023-recap-of-drug-updates/ Tue, 01 Aug 2023 20:36:31 +0000 https://www.empr.com/?p=201579 The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of July. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
BREVIBLOC (Esmolol HCl) X X X X X X    
CLINOLIPID (Lipid content)   X X X        
DROXIA (Hydroxyurea)   X   X        
GAVRETO (Pralsetinib)   X     X      
INTRALIPID (Fat emulsion) X X X  X X   X  
IPOL (Trivalent poliovirus vaccine)   X X X   X  X  
LILETTA (Levonorgestrel) X X X          
RINVOQ (Upadacitinib) X X   X X X    
SAFYRAL (Drospirenone, ethinyl estradiol, levomefolate calcium)     X X X      
ZTALMY (Ganaxolone)   X   X        
Review more drug monograph updates

]]> June 2023 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/june-2023-recap-of-drug-updates/ Fri, 07 Jul 2023 13:06:31 +0000 https://www.empr.com/?p=200261 The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of June. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
BYLVAY (Odevixibat) X X   X   X    
COREG (Carvedilol)       X X X    
INJECTAFER (Elemental iron [as ferric carboxymaltose]) X X   X        
JARDIANCE (Empagliflozin) X X            
KALYDECO (Ivacaftor) X X     X      
LINZESS (Linaclotide) X X            
PRADAXA (Dabigatran etexilate mesylate)       X   X X  
PREVYMIS (Letermovir) X X            
REXULTI (Brexpiprazole) X X   X        
SYNJARDY (Empagliflozin, metformin HCl) X X            
Review more drug monograph updates

]]> May 2023 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/may-2023-recap-of-drug-updates/ Mon, 12 Jun 2023 20:50:31 +0000 https://www.empr.com/?p=198363 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of May. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
Ayvakit  (avapritinib) X X     X X    
Dexilant  (dexlansoprazole)   X   X        
Imbruvica (ibrutinub) X X            
Lumakras (sotorasib)       X     X  
Padcev (enfortumab vedotin-ejfv)   X            
Provigil (modafinil)         X      
Rinvoq (upadacitinib)       X X X    
Trulicity (dulaglutide) X X            
Uloric (febuxostat)       X X      
Zosyn (piperacillin, tazobactam)         X      
Review more drug monograph updates

]]> April 2023 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/april-2023-recap-of-drug-updates/ Thu, 04 May 2023 13:24:02 +0000 https://www.empr.com/?p=196230 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of April. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
MENVEO (Neisseria meningitidis oligosaccharide conjugate vaccine)   X   X        
M-M-R II (Measles, mumps and rubella viruses live, attenuated) X X X X X   X   
FROVA (Frovatriptan)     X     X    
PNEUMOVAX 23 (Pneumococcal vaccine polyvalent) X X X X X X X  
PREVNAR 13 (Pneumococcal 13-valent conjugate vaccine) X X   X X   X  
PREVNAR 20 (Pneumococcal 20-valent conjugate vaccine) X X   X        
QULIPTA (Atogepant) X X   X X X    
TWINRIX (Hepatitis A inactivated, hepatitis B surface antigen [recombinant])   X   X X   X   
UBRELVY (Ubrogepant)       X        
VARIVAX (Varicella virus vaccine live, attenuated)   X            
Review more drug monograph updates

]]> March 2023 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/march-2023-recap-of-drug-updates/ Mon, 03 Apr 2023 16:51:58 +0000 https://www.empr.com/?p=194566 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of March. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
ADUHELM (Aducanumab-avwa)   X   X X      
AFREZZA (Insulin [human, recombinant]) X X   X     X   
ALVESCO (Ciclesonide)     X X   X    
ANGIOMAX (Bivalirudin) X X   X X      
EVKEEZA (Evinacumab-dgnb) X X       X    
KEVZARA (Sarilumab) X X   X        
PRECEDEX (Dexmedetomidine HCl) X X   X        
RETAVASE (Reteplase) X X X X X X X   
SPRYCEL (Dasatinib)       X X X    
ZETONNA (Ciclesonide)   X   X   X    
Review more drug monograph updates

]]> February 2023 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/february-2023-recap-of-drug-updates/ Mon, 06 Mar 2023 17:09:44 +0000 https://www.empr.com/?p=192539 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of February. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
CIBINQO (Abrocitinib) X X            
CRESTOR (Rosuvastatin [as calcium]) X X X X X      
EYLEA (Aflibercept) X X   X        
LOREEV XR (Lorazepam ext-rel)       X     X  
LOSEASONIQUE (Levonorgestrel, ethinyl estradiol)     X  X X      
MIRALAX (Polyethylene glycol [PEG] 3350) X   X X        
SEASONALE (Levonorgestrel, ethinyl estradiol)     X X X      
SEASONIQUE (Levonorgestrel, ethinyl estradiol)     X X X      
TRULICITY (Dulaglutide) X X            
XENICAL (Orlistat)   X   X        
Review more drug monograph updates

]]> January 2023 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/january-2023-recap-of-drug-updates/ Wed, 01 Feb 2023 17:49:14 +0000 https://www.empr.com/?p=191034 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of January. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
BRUKINSA (Zanubrutinib) X X   X X      
ENJAYMO (Sutimlimab-jome) X X   X   X    
LIPITOR (Atorvastatin [as calcium]) X X X X   X X   
LIVALO (Pitavastatin) X X X X        
ODACTRA (House dust mite allergen extract) X X   X   X    
RUBRACA (Rucaparib) X X   X        
TUKYSA (Tucatinib) X X     X X    
VRAYLAR (Cariprazine) X X       X    
WEGOVY (Semaglutide) X X       X    
XIGDUO XR (Dapagliflozin, metformin HCl ext-rel)       X X X    
Review more drug monograph updates

]]> December 2022 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/december-2022-recap-of-drug-updates/ Wed, 04 Jan 2023 16:31:35 +0000 https://www.empr.com/?p=189933 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
ACTEMRA (Tocilizumab) X X   X        
BREXAFEMME (Ibrexafungerp) X X   X X X    
FORANE (Isoflurane)     X X     X   
SEGLUROMET (Ertugliflozin, metformin HCl)       X X X    
STEGLUJAN (Ertugliflozin, sitagliptin)       X X X    
STENDRA (Avanafil)     X X     X X
SYNJARDY (Empagliflozin, metformin HCl)       X X X    
TYMLOS (Abaloparatide) X X       X    
ULTANE (Sevoflurane)     X X   X    
VITRAKVI (Larotrectinib)   X     X X    
Review more drug monograph updates

]]> November 2022 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/november-2022-recap-of-drug-updates/ Thu, 01 Dec 2022 21:31:06 +0000 https://www.empr.com/?p=188775 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of November. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
ADCETRIS (Brentuximab vedotin) X X       X    
ADIPEX-P (Phentermine HCl) X X X X X X X   
BYLVAY (Odevixibat)   X     X      
COTELLIC (Cobimetinib) X X       X    
EQUETRO (Carbamazepine)   X   X X      
INVOKAMET (Canagliflozin, metformin [as HCl])       X X X     
INVOKANA (Canagliflozin)       X X X    
LEVOPHED (Norepinephrine bitartrate) X X X X X X X   
LILETTA (Levonorgestrel) X X  X          
STEGLATRO (Ertugliflozin)       X X X    
Review more drug monograph updates

]]> October 2022 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/october-2022-recap-of-drug-updates/ Tue, 01 Nov 2022 18:01:43 +0000 https://www.empr.com/?p=187681 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
AVASTIN (Bevacizumab) X         X X  
BOOSTRIX (Tetanus and reduced diphtheria toxoid, acellular pertussis vaccine) X X   X   X X   
FIRDAPSE (Amifampridine) X X       X    
IMBRUVICA (Ibrutinib)   X       X    
OXLUMO (Lumasiran) X X   X        
PLAVIX (Clopidogrel [as bisulfate])       X X   X  
RELPAX (Eletriptan [as HBr]) X X X          
ROBINUL (Glycopyrrolate)   X X X X X X   
ZEJULA (Niraparib) X X        X X  
ZOMIG (Zolmitriptan) X X X           
Review more drug monograph updates

]]> September 2022 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/september-2022-recap-of-drug-updates/ Mon, 03 Oct 2022 18:59:20 +0000 https://www.empr.com/?p=186397 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of September. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
ADLYXIN (Lixisenatide) X X   X   X    
DIACOMIT (Stiripentol) X X   X        
DUPIXENT (Dupilumab) X X       X    
EFFEXOR XR (Venlafaxine HCl ext-rel)   X   X X      
IMFINZI (Durvalumab) X X   X        
OCTAGAM 5% (Immune globulin [human])   X X X X      
QUARTETTE (Levonorgestrel, ethinyl estradiol)     X X X      
RETEVMO (Selpercatinib) X X   X X X    
TRODELVY (Sacituzumab govitecan-hziy) X X    X        
ULTOMIRIS (Ravulizumab-cwvz)   X   X     X  
Review more drug monograph updates

]]> August 2022 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/august-2022-recap-of-drug-updates/ Thu, 01 Sep 2022 15:44:25 +0000 https://www.empr.com/?p=185002 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of August. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
LUTATHERA (Lutetium Lu 177 dotatate)   X   X   X    
MEKINIST (Trametinib) X X       X    
NUBEQA (Darolutamide) X X   X   X    
OPZELURA (Ruxolitinib) X X   X   X    
SKYRIZI (Risankizumab-rzaa) X X   X   X    
TAFINLAR (Dabrafenib) X X       X
   
VAXCHORA (Cholera vaccine) X X   X        
XALKORI (Crizotinib) X X   X   X    
XOFLUZA (Baloxavir marboxil) X X    X   X    
ZUBSOLV (Buprenorphine [as HCl], naloxone [as HCl dihydrate])   X   X   X    
Review more drug monograph updates

]]> July 2022 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/july-2022-recap-of-drug-updates/ Tue, 02 Aug 2022 14:15:36 +0000 https://www.empr.com/?p=183846 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of July. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
APOKYN (Apomorphine HCl)   X   X   X    
BELBUCA (Buprenorphine)   X   X   X    
BEOVU (Brolucizumab-dbll) X X         X   
EVRYSDI (Risdiplam) X X         X  
KRYSTEXXA (Pegloticase)   X   X X X    
LANTUS (Insulin glargine) X X   X X  
X  
LOPRESSOR HCT (Metoprolol tartrate, hydrochlorothiazide)     X X X X    
NAROPIN (Ropivacaine HCl)   X   X   X X   
QSYMIA (Phentermine HCl/topiramate ext-rel) X X    X X X    
SOLIQUA 100/33 (Insulin glargine, lixisenatide) X X   X   X    
Review more drug monograph updates

]]> June 2022 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/june-2022-recap-of-drug-updates/ Tue, 05 Jul 2022 17:34:25 +0000 https://www.empr.com/?p=182699 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of June. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
BREYANZI (Lisocabtagene maraleucel) X X   X   X    
DUPIXENT (Dupilumab) X X            
IMCIVREE (Setmelanotide) X X   X        
KYMRIAH (Tisagenlecleucel) X X       X    
MIGRANAL (Dihydroergotamine mesylate)   X X  X   X    
OLUMIANT (Baricitinib) X X   X     X
    
RIABNI (Rituximab-arrx) X X       X    
TIBSOVO (Ivosidenib) X X   X        
VIDAZA (Azacitidine) X X    X   X    
VAXNEUVANCE (Pneumococcal 15-valent vaccine)   X   X        
Review more drug monograph updates

]]> May 2022 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/may-2022-recap-of-drug-updates/ Wed, 01 Jun 2022 17:40:50 +0000 https://www.empr.com/?p=181477 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of May. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
BALVERSA (Erdafitinib)       X X   X  
ENHERTU (Fam-trastuzumab deruxtecan-nxki) X X   X   X    
EPIDUO FORTE GEL (Adapalene, benzoyl peroxide) X X   X   X    
LUPRON DEPOT-PED (Leuprolide acetate)       X    X X  
METADATE CD (Methylphenidate HCl)     X  X X X    
QELBREE (Viloxazine)   X   X     X
    
RINVOQ (Upadacitinib) X     X   X    
SUPPRELIN LA (Histrelin acetate)       X   X    
TRIPTODUR (Triptorelin pamoate)       X   X    
TRIUMEQ (Abacavir, dolutegravir, lamivudine) X X   X X X X  
Review more drug monograph updates

]]> April 2022 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/april-2022-recap-of-drug-updates/ Mon, 02 May 2022 21:50:48 +0000 https://www.empr.com/?p=180199 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of April. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
ANCOBON (Flucytosine)   X X X        
CAPLYTA (Lumateperone)   X   X X      
CAPRELSA (Vandetanib)   X   X   X    
MAYZENT (Siponimod)     X   X   X  
PROCYSBI (Cysteamine bitartrate)       X   X    
PROMACTA (Eltrombopag [as olamine])   X         X
 X  
STROMECTOL (Ivermectin)   X   X   X X  
ULTANE (Sevoflurane)       X X X    
VISIPAQUE 320 (Iodixanol) X X
  X X X X   
YESCARTA (Axicabtagene ciloleucel) X X   X        
Review more drug monograph updates

]]> March 2022 Recap of Drug Updates https://www.empr.com/home/news/drug-monograph-updates/march-2022-recap-of-drug-updates/ Fri, 01 Apr 2022 16:48:36 +0000 https://www.empr.com/?p=178920 .telerik-reTable-2 { border-collapse: collapse; border: solid 0px; font-family: Tahoma; } .telerik-reTable-2 tr.telerik-reTableHeaderRow-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableHeaderFirstCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderLastCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderOddCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableHeaderEvenCol-2 { border-width: 1.0pt 1.0pt 3.0pt 1.0pt; border: solid white 1.0pt; border-bottom: solid white 3.0pt; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableOddRow-2 { color: #666666; background-color: #F2F3F4; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 tr.telerik-reTableEvenRow-2 { color: #666666; background-color: #E7EBF7; font-size: 10pt; vertical-align: top; } .telerik-reTable-2 td.telerik-reTableFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 tr.telerik-reTableFooterRow-2 { color: #666666; background-color: #FFFFFF; font-size: 10pt; vertical-align: top; padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterFirstCol-2 { margin-top: 0in; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; line-height: 115%; font-size: 11.0pt; font-family: "Calibri" , "sans-serif"; width: 119.7pt; border-top: none; border-left: solid white 1.0pt; border-bottom: none; border-right: solid white 3.0pt; background: #4F81BD; padding: 0in 5.4pt 0in 5.4pt; color: #FFFFFF; } .telerik-reTable-2 td.telerik-reTableFooterLastCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterOddCol-2 { padding: 0in 5.4pt 0in 5.4pt; } .telerik-reTable-2 td.telerik-reTableFooterEvenCol-2 { padding: 0in 5.4pt 0in 5.4pt; }

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of March. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME UPDATES
(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
ALOPRIM (Allopurinol [as sodium])   X X X X X    
ARTESUNATE FOR INJECTION (Artesunate)       X   X X   
ASTEPRO ALLERGY (Azelastine HCl) X X   X X X X   
CELEXA (Citalopram [as HBr])   X   X    X    
CONRAY (Iothalamate meglumine) X X   X     X  
FINTEPLA (Fenfluramine) X X   X X  
   
KAZANO (Alogliptin, metformin [as HCl])   X X X        
OZEMPIC (Semaglutide)   X   X   X    
RISPERDAL (Risperidone)   X
  X     X   
XIGDUO XR (Dapagliflozin, metformin HCl ext-rel) X X   X X X    
Review more drug monograph updates

]]>